Gufic BioSciences Ltd

NSE: GUFICBIO · BSE: 509079 · Pharmaceuticals & Biotechnology · 33 announcements

Share price: ₹424.00
Market cap: ₹4,252 Cr
Revenue (annual): ₹944.0 Cr
Net profit (annual): ₹64.21 Cr
P/E (TTM): 57.9×Sector 47.4×
Promoter holding: 72.50%+0.00% QoQ
FII holding: 0.47%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

29 Apr 2026 14:42 IST NSE

Gufic BioSciences Acquisition Worth ₹0.47 Cr

Gufic Biosciences Limited invested USD 50,000 (₹0.47 Crore) to acquire 3,78,350 additional shares in Australian biotech firm Selvax Pty Ltd. This strategic move aims to develop novel immunotherapy treatments for solid tumours. Following this transaction, Gufic's total holding in Selvax reached 16,85,350 shares, strengthening its oncology and biotechnology portfolio.

Value: ₹0.47 Cr

Read the filing ↗

7 Apr 2026 12:01 IST NSE

Other Announcement

Gufic BioSciences Other Announcement

Gufic Biosciences Limited submitted its quarterly compliance certificate for the period ended March 31, 2026. Issued by MUFG Intime India, the certificate confirms that securities received for dematerialisation were processed and listed on the stock exchanges. No shareholder requests were received during the quarter.

Read the filing ↗

3 Apr 2026 19:13 IST BSE

Legal & Regulatory

Gufic BioSciences Legal & Regulatory

Gufic Biosciences received an income tax order reducing a prior demand to Rs. 11.76 Lakhs, but imposing a penalty of Rs. 23.52 Lakhs (0.24 Cr) for under-reported income. The company intends to appeal the decision before the Commissioner of Income Tax (Appeals) based on tax consultant advice.

Value: ₹0.24 Cr

Read the filing ↗